Literature DB >> 10945503

Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.

F Romerio1, A Riva, D Zella.   

Abstract

Interferon (IFN)-alpha affects the growth, differentiation and function of various cell types by transducing regulatory signals through the Janus tyrosine kinase/signal transducers of activation and transcription (Jak/STAT) pathway. The signalling pathways employing the mitogen-activated ERK-activating kinase (MEK) and the extracellular-regulated kinase (ERK) are critical in growth factors signalling. Engagement of the receptors, and subsequent stimulation of Ras and Raf, initiates a phosphorylative cascade leading to activation of several proteins among which MEK and ERK play a central role in routing signals critical in controlling cell development, activation and proliferation. We demonstrate here that 24-48 h following treatment of transformed T- and monocytoid cell lines with recombinant human IFN-alpha2b both the phosphorylation and activity of MEK1 and its substrates ERK1/2 were reduced. In contrast, the activities of the upstream molecules Ras and Raf-1 were not affected. No effect on MEK/ERK activity was observed upon short-term exposure (1-30 min) to IFN. The anti-proliferative effect of IFN-alpha was increased by the addition in the culture medium of a specific inhibitor of MEK, namely PD98059. In conclusion, our results indicate that IFN-alpha regulates the activity of the MEK/ERK pathway and consequently modulates cellular proliferation through a Ras/Raf-independent mechanism. Targeting the MEK/ERK pathway may strengthen the IFN-mediated anti-cancer effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945503      PMCID: PMC2374650          DOI: 10.1054/bjoc.2000.1263

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Activation of the MAP kinase pathway by the protein kinase raf.

Authors:  L R Howe; S J Leevers; N Gómez; S Nakielny; P Cohen; C J Marshall
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

2.  Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases.

Authors:  N Gómez; P Cohen
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

3.  Convenient assay for interferons.

Authors:  S Rubinstein; P C Familletti; S Pestka
Journal:  J Virol       Date:  1981-02       Impact factor: 5.103

4.  Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase.

Authors:  N G Anderson; J L Maller; N K Tonks; T W Sturgill
Journal:  Nature       Date:  1990-02-15       Impact factor: 49.962

5.  Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells.

Authors:  D Resnitzky; N Tiefenbrun; H Berissi; A Kimchi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

6.  Raf-1 activates MAP kinase-kinase.

Authors:  J M Kyriakis; H App; X F Zhang; P Banerjee; D L Brautigan; U R Rapp; J Avruch
Journal:  Nature       Date:  1992-07-30       Impact factor: 49.962

7.  Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.

Authors:  P Dent; W Haser; T A Haystead; L A Vincent; T M Roberts; T W Sturgill
Journal:  Science       Date:  1992-09-04       Impact factor: 47.728

8.  Phosphorylation of Xenopus mitogen-activated protein (MAP) kinase kinase by MAP kinase kinase kinase and MAP kinase.

Authors:  S Matsuda; Y Gotoh; E Nishida
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.157

9.  A protein factor for ras p21-dependent activation of mitogen-activated protein (MAP) kinase through MAP kinase kinase.

Authors:  T Itoh; K Kaibuchi; T Masuda; T Yamamoto; Y Matsuura; A Maeda; K Shimizu; Y Takai
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

10.  Insulin stimulation of gene expression mediated by p21ras activation.

Authors:  B M Burgering; R H Medema; J A Maassen; M L van de Wetering; A J van der Eb; F McCormick; J L Bos
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

View more
  8 in total

Review 1.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Authors:  Stefan Kaluz; Milota Kaluzová; Shu-Yuan Liao; Michael Lerman; Eric J Stanbridge
Journal:  Biochim Biophys Acta       Date:  2009-01-22

2.  Total chemical synthesis of human interferon alpha-2b via native chemical ligation.

Authors:  Jing Li; Clara Lehmann; Xishan Chen; Fabio Romerio; Wuyuan Lu
Journal:  J Pept Sci       Date:  2015-03-24       Impact factor: 1.905

3.  Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387.

Authors:  Yuxin Wang; Jing Nan; Belinda Willard; Xin Wang; Jinbo Yang; George R Stark
Journal:  EMBO J       Date:  2016-11-16       Impact factor: 11.598

Review 4.  EMT and Inflammation: Crossroads in HCC.

Authors:  Burcu Sengez; Brian I Carr; Hani Alotaibi
Journal:  J Gastrointest Cancer       Date:  2022-01-12

Review 5.  Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.

Authors:  Fei Xiong; Qi Wang; Guan-Hua Wu; Wen-Zheng Liu; Bing Wang; Yong-Jun Chen
Journal:  Biomark Res       Date:  2022-09-14

6.  PML-II regulates ERK and AKT signal activation and IFNα-induced cell death.

Authors:  Xueqiong Meng; Yixiang Chen; Salvador Macip; Keith Leppard
Journal:  Cell Commun Signal       Date:  2021-07-02       Impact factor: 5.712

Review 7.  Human interferon alpha-2b: a therapeutic protein for cancer treatment.

Authors:  Ratih Asmana Ningrum
Journal:  Scientifica (Cairo)       Date:  2014-03-10

8.  TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma.

Authors:  Sifan Yu; Tianxiao Xu; Jie Dai; Meng Ma; Huan Tang; Zhihong Chi; Lu Si; Chuanliang Cui; Xinan Sheng; Yan Kong; Jun Guo
Journal:  Onco Targets Ther       Date:  2018-07-17       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.